Corcept Therapeutics and Merck are noted as peers within the pharmaceuticals segment.
2 reports, 1 independent
Updated Jul 27
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Corcept Therapeutics and Merck are noted as peers within the pharmaceuticals segment.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Corcept Therapeutics
American pharmaceutical company
-
Merck
public company in Indonesia
Related events
- Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.
- Corcept Therapeutics and Twist Bioscience are noted as holdings within the First Trust biotech fund.
- Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.
- Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
Coverage
Newest first; wire copies grouped- StockStoryWhat To Expect From Corcept’s (CORT) Q2 Earnings Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting earnings this Thursday after the bell. Here’s what investors should know. Corce